Abstract 2066P
Background
This study aimed to assess the usefulness of ChatGPT and Perplexity's responses to frequently asked questions regarding the diagnosis and treatment of rectal cancer.
Methods
Both artificial intelligence systems were asked 20 questions covering disease risk factors, screening, symptoms, treatment, and treatment side effects. In accordance with the ESMO patient guides, the questions were posed in the order specified. According to ESMO patient guide recommendations, responses were graded as “appropriate,” “inappropriate,” or “insufficient.”
Results
While ChatGPT provided appropriate responses to 17 of the questions (85%), the responses to two questions (10%) were deemed inappropriate, and the response to one question (5%) was deemed insufficient. Nineteen (95%) of Perplexity's responses were deemed appropriate. It was determined that both artificial intelligence systems responded improperly to the nutrition question.
Conclusions
The study's findings indicate that ChatGPT and Perplexity provide patients with accurate information about rectal cancer. The accuracy rate of Perplexity was found to be higher than that of ChatGPT. It can be demonstrated that the benefit of Perplexity is that it displays the source for each piece of information. However, especially cancer patients require emotional and psychological assistance, and further research is required to determine the impact of these artificial intelligence systems on the patient's psychology. Moreover, given the complexity and individuality of medical care, AI chatbots should not be viewed as a replacement for medical professionals, but rather as a supplement that can help patients gain access to trustworthy information and support. Overall, this study contributes to the growing body of literature on AI chatbots and their potential use in cancer by highlighting both the advantages and disadvantages of these technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06